Samuel Agresta, M.D., M.P.H.
Dr. Agresta has an established track record of global clinical drug development in solid tumors and hematologic malignancies, including recent approval of multiple cancer medicines. Dr. Agresta is currently Chief Medical Officer of Foghorn Therapeutics. Prior to Foghorn, Dr. Agresta served as Chief Medical Officer of Infinity where he led the company’s clinical strategy including the design of MARIO-3 and MARIO-275, Infinity’s Phase 2 clinical studies IPI-549. Prior to Infinity, Dr. Agresta was vice president and head of clinical development at Agios Pharmaceuticals, Inc. During Dr. Agresta’s six plus years at Agios, he was responsible for the successful development of novel targeted oncology medicines, including IDHiFA® for patients with IDH2 mutation positive AML and TIBSOVO® for patients with IDH1 mutation positive AML, as well as the development of the targeted agent, AG-348, currently in Phase 3 development for patients with pyruvate kinase deficiency, a rare genetic disease. Prior to Agios, Dr. Agresta held positions of responsibility in oncology clinical development, Phases I-III, at Merrimack Pharmaceutical and Genentech, Inc., including the development of Onivyde®, for patients with pancreatic cancer and Kadcyla®, a novel targeted oncology medicine for patients with HER2 positive breast cancer. Prior to his industry experience, Dr. Agresta was on the oncology faculty at the Moffitt Cancer Center where he specialized in adolescent sarcoma care and participated in numerous industry trials.
Dr. Agresta received his medical degree, internal medicine training, and served as chief resident at Tulane University School of Medicine in New Orleans. While in medical school, he also received a Master’s Degree in Public Health and Tropical Medicine from Tulane University School of Public Health. He completed his medical oncology fellowship at the University of South Florida and Moffitt Cancer Center Cancer where he also received a Master’s Degree in Clinical Investigation from the University of South Florida.
David Beier, J.D.
David Beier, J.D., is a Managing Director of Bay City Capital and brings a wealth of experience to the Infinity Board. David serves as an advisor to the Parker Institute for Cancer Immunotherapy, a Senior Fellow at the USC Schaeffer Center for Health Policy & Economics and as a member of the Board of Directors of Arcus Biosciences, UCSF Benioff Children’s Hospitals and the California Life Sciences Association. He also serves as an appointee of Governor Brown on the California State Government Organization and the Economy Commission. Having spent two decades as part of the senior management teams for Amgen and Genentech, he brings invaluable perspective regarding strategy for entrepreneurial biotechnology firms and the industry in general as a globally recognized leader in health care policy, regulatory affairs, healthcare economics, and pricing. Mr. Beier also previously served in the White House during the Clinton Administration as a Chief Domestic Policy Advisor to the Vice President.
Anthony Evnin, Ph.D.
Anthony Evnin, Ph.D., has been a Partner of Venrock, a venture capital firm, since 1975. Dr. Evnin currently serves on the Board of Directors of AVEO Pharmaceuticals, Constellation Pharmaceuticals and Cantel Medical as well as on the Board of two private companies, Bridge Medicines and Redpin Therapeutics. He is a Member of the Boards of Overseers and Managers of Memorial Sloan Kettering Cancer Center, a Trustee Emeritus of The Rockefeller University, a Trustee of The Jackson Laboratory, a Director of the New York Genome Center, a Member of the Board of Directors of the Albert and Mary Lasker Foundation, and a Trustee Emeritus of Princeton University. Dr. Evnin received an A.B. in chemistry from Princeton University and a Ph.D. in chemistry from the Massachusetts Institute of Technology.
Richard Gaynor, M.D.
Richard Gaynor, M.D. is currently the President of Research and Development for Neon Therapeutics (NasdaqGS: NTGN), a biotechnology company developing novel neoantigen-targeted T cell therapies. Prior to his tenure at Neon Therapeutics, Dr. Gaynor spent 15 years in a series of senior roles at Lilly Oncology, most recently as Senior Vice President Clinical Development and Medical Affairs, where he chaired the Lilly Oncology Research and Development Committee and helped oversee a variety of collaborations, including with Bristol-Myers Squibb, Merck, AstraZeneca and GE. Prior to that role, Dr. Gaynor also led preclinical and early clinical oncology research at Eli Lilly. Dr. Gaynor began his career in academia, spending nine years on the faculty at UCLA School of Medicine, followed by 11 years on the faculty at the University of Texas Southwestern Medical School, including time serving as the chief of hematology-oncology and director of the Simmons Cancer Center. He holds an M.D. from the University of Texas Southwestern Medical School and, following his residency in internal medicine there, he completed fellowship training in hematology-oncology at the UCLA School of Medicine. He is the author of nearly 150 publications and participates on numerous advisory boards and committees, including the American Association of Cancer Research, the Stand Up To Cancer scientific advisory committee, and the Damon Runyon Cancer Research Foundation. Dr. Gaynor also serves on the board of directors of Alkermes plc.
Adelene Perkins serves as Infinity’s chief executive officer and Infinity’s chair, a position she has held since 2012. She was named chief executive officer and elected to the Board of Directors in 2009. Prior to becoming Infinity’s chief executive officer, Ms. Perkins served as Infinity’s President, a position she held since 2008. Ms. Perkins joined Infinity in June 2002 as executive vice president and chief business officer.
Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she served as vice president of business and corporate development and an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, from 1992-1999, she was at Genetics Institute, now a unit of Pfizer, where she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEase™ business unit. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined Genetics Institute in corporate and business development where she led corporate and product strategy initiatives. From 1985-1992, Ms. Perkins worked at Bain & Company, an international strategy consulting firm, where she provided strategic and operational advice to clients in the healthcare industry.
Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Boards of BIO (Biotechnology Industry Organization), the Massachusetts Biotechnology Council, Bruker Corporation; and is the Vice Chairman of the Board of Project Hope, a multi-service agency committed to breaking the cycle of homelessness and poverty. She is a past member of the Boards of Padlock Therapeutics and the Massachusetts Life Science Center.
Norman C. Selby has spent over 35 years in the healthcare world in a variety of consulting, managerial, investor and Board roles. His primary activities today are centered on two companies he helped found: Paige.AI, the leading artificial intelligence company in pathology, and Real Endpoints LLC, an information and analytics company focused on the changing pharmaceutical reimbursement and market access landscape. In addition to being the Lead Independent Director of Infinity, he is also on the Boards of Escalier Bioscience and Oppilan Pharma Ltd. Among earlier roles, Mr. Selby has served as the CEO of TransForm Pharmaceuticals, Inc., Executive Chairman of Windhover Information, Founder and Executive Chairman of Physicians Interactive Holdings, and as a board member of Millennium Pharmaceuticals.
Mr. Selby spent the bulk of his career at McKinsey & Company where he was Director (Senior Partner) in the firm’s New York office, and head of the firm’s Global Pharmaceuticals and Medical Products Practice. From 1987-1989, Mr. Selby took a leave of absence from McKinsey to serve as Chief Operating Officer of the New York Blood Center, the largest community blood organization in the country, where he led its financial and operational turnaround.
Mr. Selby serves on the Board of Trustees of the Central Park Conservancy and the Memorial Sloan-Kettering Cancer Center, and is a member of the Council on Foreign Relations, all based in New York City. He is also on the Advisory Board of the Harvard Business School’s Healthcare Initiative. Mr. Selby holds a B.A. in Architecture from Yale College and an M.B.A. with Distinction from the Harvard Graduate School of Business Administration.
Michael Venuti, Ph.D.
Michael Venuti, Ph.D., chair of Infinity’s Research and Development Committee, is a consultant on drug discovery and development to biotechnology companies and venture capital groups. Previously, he was chief scientific officer of NeuroTherapeutics Pharma, from July 2011 to June 2013. From June 2010 to April 2011, Dr. Venuti served as president and chief executive officer of iPierian, Inc., a private biopharmaceutical company, after joining the company as president and chief scientific officer in February 2010. Prior to joining iPierian, Dr. Venuti served as chief executive officer and member of the board of directors of BioSeek, Inc., which was acquired by Asterand plc in February 2010. He previously served as chief executive officer and member of the board of directors of Discovery Partners International, a small molecule-based drug discovery services company. Dr. Venuti led the merger of Discovery Partners into Infinity Pharmaceuticals in 2006. From 2001 through 2005, he held positions as senior vice president, business development and Pharmacogenomics, and senior vice president, research and preclinical development at Celera Genomics, and served as the general manager of Celera South San Francisco. He served as senior vice president, research and preclinical development, at Axys Pharmaceuticals prior to its acquisition by Celera. Prior to joining Axys, Dr. Venuti was director of Bioorganic Chemistry at Genentech, Inc., and began his research career in medicinal chemistry at Syntex Research. Dr. Venuti holds an A.B. from Dartmouth College, and a Ph.D. in Organic Chemistry from The Massachusetts Institute of Technology.